Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease
Copyright © 2022 Elsevier Ltd. All rights reserved..
BACKGROUND: Although nearly all Australian children are vaccinated against pneumococcal disease, pneumococcal vaccine uptake is low among high-risk adults. This study aimed to identify perceived barriers to pneumococcal vaccination among high-risk adults.
METHODS: This paper reports combined data on pneumococcal vaccination collected from three different online, cross-sectional surveys that were administered in Australia between August 2019 and September 2020. Using Poisson regression, we identified characteristics and beliefs associated with self-reported pneumococcal vaccination among adults aged 65 and over or with chronic health conditions.
RESULTS: The weighted estimate for pneumococcal vaccine coverage was 24% for high-risk adults under 65 and 53% for adults aged 65 and over. Nearly half of those under 65 reported they had never heard of the pneumococcal vaccine, while 26% of those aged 65 and over had never heard of the vaccine. Among those under 65, pneumococcal vaccination was associated with high perceived disease susceptibility (PR = 1.97, 95% CI: 1.23, 3.18), not having heard of the pneumococcal vaccine (PR = 0.44, 95% CI: 0.28-0.69), awareness that their chronic health condition puts them at increased risk of pneumonia (PR = 2.44, 95% CI: 1.51-3.98), and having a doctor recommend the vaccine (PR = 3.02, 95% CI: 2.05-4.44). Among adults aged 65 and over, self-reported pneumococcal vaccination was associated with influenza vaccination in the previous 12 months (PR = 4.28, 95% CI: 2.85-6.44) and awareness that they are eligible for free pneumococcal vaccination (PR = 5.02, 95% CI: 2.34-10.77).
CONCLUSION: Awareness of pneumococcal vaccines was low among adults at high risk of pneumococcal disease, which appears to be contributing to low vaccine uptake. A doctor's recommendation was associated with increased uptake of pneumococcal vaccine, so interventions should be developed to promote pneumococcal vaccine uptake in GP practices.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Vaccine - 40(2022), 8 vom: 16. Feb., Seite 1152-1161 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trent, Mallory J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult Vaccination |
|---|
| Anmerkungen: |
Date Completed 10.03.2022 Date Revised 11.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2022.01.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336131062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336131062 | ||
| 003 | DE-627 | ||
| 005 | 20231225231435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2022.01.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336131062 | ||
| 035 | |a (NLM)35078659 | ||
| 035 | |a (PII)S0264-410X(22)00026-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trent, Mallory J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2022 | ||
| 500 | |a Date Revised 11.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Although nearly all Australian children are vaccinated against pneumococcal disease, pneumococcal vaccine uptake is low among high-risk adults. This study aimed to identify perceived barriers to pneumococcal vaccination among high-risk adults | ||
| 520 | |a METHODS: This paper reports combined data on pneumococcal vaccination collected from three different online, cross-sectional surveys that were administered in Australia between August 2019 and September 2020. Using Poisson regression, we identified characteristics and beliefs associated with self-reported pneumococcal vaccination among adults aged 65 and over or with chronic health conditions | ||
| 520 | |a RESULTS: The weighted estimate for pneumococcal vaccine coverage was 24% for high-risk adults under 65 and 53% for adults aged 65 and over. Nearly half of those under 65 reported they had never heard of the pneumococcal vaccine, while 26% of those aged 65 and over had never heard of the vaccine. Among those under 65, pneumococcal vaccination was associated with high perceived disease susceptibility (PR = 1.97, 95% CI: 1.23, 3.18), not having heard of the pneumococcal vaccine (PR = 0.44, 95% CI: 0.28-0.69), awareness that their chronic health condition puts them at increased risk of pneumonia (PR = 2.44, 95% CI: 1.51-3.98), and having a doctor recommend the vaccine (PR = 3.02, 95% CI: 2.05-4.44). Among adults aged 65 and over, self-reported pneumococcal vaccination was associated with influenza vaccination in the previous 12 months (PR = 4.28, 95% CI: 2.85-6.44) and awareness that they are eligible for free pneumococcal vaccination (PR = 5.02, 95% CI: 2.34-10.77) | ||
| 520 | |a CONCLUSION: Awareness of pneumococcal vaccines was low among adults at high risk of pneumococcal disease, which appears to be contributing to low vaccine uptake. A doctor's recommendation was associated with increased uptake of pneumococcal vaccine, so interventions should be developed to promote pneumococcal vaccine uptake in GP practices | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adult Vaccination | |
| 650 | 4 | |a Barriers | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a High-risk | |
| 650 | 4 | |a Pneumococcal disease | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a Vaccine Hesitancy | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 700 | 1 | |a Salmon, Daniel A |e verfasserin |4 aut | |
| 700 | 1 | |a MacIntyre, C Raina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 40(2022), 8 vom: 16. Feb., Seite 1152-1161 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:8 |g day:16 |g month:02 |g pages:1152-1161 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2022.01.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 8 |b 16 |c 02 |h 1152-1161 | ||